2019
Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*
Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*. Leukemia & Lymphoma 2019, 60: 2927-2930. PMID: 31119966, DOI: 10.1080/10428194.2019.1612061.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaIncidence of mucositisAddition of leucovorinSkin reactionsLeucovorin administrationMucositis incidenceMucositis occurrenceDisease stabilizationAdverse eventsClinical responseCTCL patientsPoor prognosisLeucovorinMucositisPatientsResponse rateLymphomaPralatrexateIncidenceEfficacyPrognosisDosingAdministration
2012
Immunotherapy for Cutaneous T-Cell Lymphoma
Modi B, Foss F, Edelson R, Girardi M. Immunotherapy for Cutaneous T-Cell Lymphoma. Contemporary Hematology 2012, 307-316. DOI: 10.1007/978-1-62703-170-7_18.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaToll-like receptor agonistsEffector T cell activityImmune effector mechanismsT cell activityGoal of therapyCytokine-based therapiesHistone deacetylase inhibitorsClinical responseMost patientsImmunotherapeutic approachesInterleukin-12Receptor agonistEffector mechanismsInterleukin-2Therapeutic approachesImmune functionDeacetylase inhibitorsTherapyCTCLPatientsLymphomaAttractive targetImmunotherapy
2005
Cross-Comparison of Patch Test and Lymphocyte Proliferation Responses in Patients With a History of Acute Generalized Exanthematous Pustulosis
Girardi M, Duncan KO, Tigelaar RE, Imaeda S, Watsky KL, McNiff JM. Cross-Comparison of Patch Test and Lymphocyte Proliferation Responses in Patients With a History of Acute Generalized Exanthematous Pustulosis. American Journal Of Dermatopathology 2005, 27: 343-346. PMID: 16121058, DOI: 10.1097/01.dad.0000160982.75176.6c.Peer-Reviewed Original ResearchConceptsAcute generalized exanthematous pustulosisPatch test resultsPositive patch test resultsGeneralized exanthematous pustulosisLymphocyte proliferative responsesProliferative responseExanthematous pustulosisPeripheral T-cell proliferative responsesT cell-mediated immune responsesDrug-specific T cellsVitro lymphocyte proliferative responseCalcium channel blocker diltiazemCell-mediated immune responsesDelayed-type hypersensitivity reactionT cell proliferative responsesAdverse cutaneous reactionsLymphocyte proliferation responseChannel blocker diltiazemCell proliferative responsesPatch test sitesNeutrophilic pustulesClinical responsePerivascular lymphocytesCutaneous reactionsHypersensitivity reactions
2004
TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909.
Kim Y, Girardi M, Duvic M, Kuzel T, Rook A, Link B, Pinter-Brown L, Comerci C, McAuley S, Schmalbach T. TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909. Blood 2004, 104: 743. DOI: 10.1182/blood.v104.11.743.743.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaCPG 7909Progressive diseaseClinical responseStable diseasePartial responseComplete responseAdvanced cutaneous T-cell lymphomaModerate flu-like symptomsGlobal assessmentLocal injection site reactionsCTC grade 1More systemic therapiesObjective clinical responsesPhysician global assessmentDurability of responseFlu-like symptomsInjection site reactionsNK cell functionPhase II portionWeeks of treatmentResults of patientsT-cell lymphomaGamma-glutamyl transferaseImmunomodulator treatment